A Review of Modeling Approaches to Predict Drug Response in Clinical Oncology

被引:13
作者
Park, Kyungsoo [1 ]
机构
[1] Yonsei Univ, Coll Med, Dept Pharmacol, 50-1 Yonsei Ro, Seoul 03722, South Korea
关键词
Model-based approaches; drug development; drug treatment; chemotherapeutic drug; PROGRESSION-FREE SURVIVAL; SURROGATE END-POINT; PHARMACODYNAMIC MODEL; TUMOR-GROWTH; DISEASE PROGRESSION; CANCER-PATIENTS; CHEMOTHERAPY; SIZE; TIME; PHARMACOKINETICS;
D O I
10.3349/ymj.2017.58.1.1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Model-based approaches have emerged as important tools for quantitatively understanding temporal relationships between drug dose, concentration, and effect over the course of treatment, and have now become central to optimal drug development and tailored drug treatment. In oncology, the therapeutic index of a chemotherapeutic drug is typically narrow and a full dose-response relationship is not available, often because of treatment failure. Noting the benefits of model-based approaches and the low therapeutic index of oncology drugs, in recent years, modeling approaches have been increasingly used to streamline oncologic drug development through early identification and quantification of dose-response relationships. With this background, this report reviews publications that used model-based approaches to evaluate drug treatment outcome variables in oncology therapeutics, ranging from tumor size dynamics to tumor/biomarker time courses and survival response.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 43 条
  • [21] Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
    Houk, Brett E.
    Bello, Carlo L.
    Poland, Bill
    Rosen, Lee S.
    Demetri, George D.
    Motzer, Robert J.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (02) : 357 - 371
  • [22] Optimizing drug regimens in cancer chemotherapy by an efficacy-toxicity mathematical model
    Iliadis, A
    Barbolosi, D
    [J]. COMPUTERS AND BIOMEDICAL RESEARCH, 2000, 33 (03): : 211 - 226
  • [23] Jonsson F, 2010, LONGITUDINAL TUMOR G
  • [24] Kanefendt F, 2012, MODELING SUNITINIB B
  • [25] A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080
    Keizer, Ron J.
    Gupta, Anubha
    Mac Gillavry, Melvin R.
    Jansen, Mendel
    Wanders, Jantien
    Beijnen, Jos H.
    Schellens, Jan H. M.
    Karlsson, Mats O.
    Huitema, Alwin D. R.
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2010, 37 (04) : 347 - 363
  • [26] Overview: Progression-Free Survival as an Endpoint in Clinical Trials with Solid Tumors
    Korn, Ronald L.
    Crowley, John J.
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (10) : 2607 - 2612
  • [27] Estimation of Renal Cell Carcinoma Treatment Effects From Disease Progression Modeling
    Maitland, M. L.
    Wu, K.
    Sharma, M. R.
    Jin, Y.
    Kang, S. P.
    Stadler, W. M.
    Karrison, T. G.
    Ratain, M. J.
    Bies, R. R.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 (04) : 345 - 351
  • [28] Phase II studies of modern drugs directed against new targets: If you are fazed, too, then resist RECIST
    Ratain, MJ
    Eckhardt, SG
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (22) : 4442 - 4445
  • [29] A Review of Mixed-Effects Models of Tumor Growth and Effects of Anticancer Drug Treatment Used in Population Analysis
    Ribba, B.
    Holford, N. H.
    Magni, P.
    Troconiz, I.
    Gueorguieva, I.
    Girard, P.
    Sarr, C.
    Elishmereni, M.
    Kloft, C.
    Friberg, L. E.
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2014, 3 (05):
  • [30] A Tumor Growth Inhibition Model for Low-Grade Glioma Treated with Chemotherapy or Radiotherapy
    Ribba, Benjamin
    Kaloshi, Gentian
    Peyre, Mathieu
    Ricard, Damien
    Calvez, Vincent
    Tod, Michel
    Cajavec-Bernard, Branka
    Idbaih, Ahmed
    Psimaras, Dimitri
    Dainese, Linda
    Pallud, Johan
    Cartalat-Carel, Stephanie
    Delattre, Jean-Yves
    Honnorat, Jerome
    Grenier, Emmanuel
    Ducray, Francois
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (18) : 5071 - 5080